LBA22 - Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial

J O’Shaughnessy,G.S Wright,A Thummala,M Danso,L.S Popovic,T Pluard,H.S Han,Z Vojnovic,N Vasev,L Ma,D.A Richards,S Wilks,D.M Milenkovic,J.A Sorrentino,Z Yang,J.K Horton,A.R Tan

doi:10.1093/annonc/mdz394.011

LBA22 - Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial

J O’Shaughnessy, G.S Wright + Show 15 more

Open Access

https://doi.org/10.1093/annonc/mdz394.011

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 1	License type: publisher-specific-oa

Affiliation: Texas Oncology, Comprehensive Cancer Centers of Nevada, Virginia Oncology Associates, Saint Luke's Hospital, Opća Bolnica Varaždin, PHI University Psychiatric Clinic - Skopje, Rocky Mountain Cancer Centers, University of Nis

#Research Grant #Gemcitabine/carboplatin + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA22 - Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial

Full Text